Cancer vaccines: the next immunotherapy frontier
MJ Lin, J Svensson-Arvelund, GS Lubitz, A Marabelle… - Nature cancer, 2022 - nature.com
After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …
Immune checkpoint therapy—current perspectives and future directions
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …
patients and conferred durable clinical benefits, including cure in a subset of patients …
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
T Todo, H Ito, Y Ino, H Ohtsu, Y Ota, J Shibahara… - Nature medicine, 2022 - nature.com
Abstract This investigator-initiated, phase 2, single-arm trial primarily assessed the efficacy
of G47∆, a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult …
of G47∆, a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult …
Therapy with oncolytic viruses: progress and challenges
Oncolytic viruses (OVs) are an emerging class of cancer therapeutics that offer the benefits
of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads …
of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads …
The next decade of immune checkpoint therapy
P Sharma, BA Siddiqui, S Anandhan, SS Yadav… - Cancer discovery, 2021 - AACR
Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
Signal pathways of melanoma and targeted therapy
W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Immune-checkpoint inhibitors and chimeric antigen receptor (CAR) T cells are
revolutionizing oncology and haematology practice. With these and other immunotherapies …
revolutionizing oncology and haematology practice. With these and other immunotherapies …
Oncolytic virotherapy: basic principles, recent advances and future directions
D Lin, Y Shen, T Liang - Signal transduction and targeted therapy, 2023 - nature.com
Oncolytic viruses (OVs) have attracted growing awareness in the twenty-first century, as they
are generally considered to have direct oncolysis and cancer immune effects. With the …
are generally considered to have direct oncolysis and cancer immune effects. With the …
Oncolytic viruses for cancer immunotherapy
O Hemminki, JM Dos Santos, A Hemminki - Journal of hematology & …, 2020 - Springer
In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in
general, with a particular focus on adenoviruses. These serve as a model to elucidate how …
general, with a particular focus on adenoviruses. These serve as a model to elucidate how …
Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma
Simple Summary Talimogene laherparepvec (T-VEC; IMLYGIC®, Amgen Inc.) is the first
oncolytic viral immunotherapy to be approved for the local treatment of unresectable …
oncolytic viral immunotherapy to be approved for the local treatment of unresectable …